Serum concentrations of IL-2 and TNF-α in patients with painful bone metastases: Correlation with responses to89SrCl2 therapy

Journal of Nuclear Medicine

Volumn 47, Issue 2, 2006, Pages 242-246

  Fang, Na ^a,c   Li, Yong ^a   Xu, Yan Song ^a   Ma, Duo ^a   Fu, Peng ^a   Gao, Hui Qi ^a   Gao, Feng Tong ^b   Yang, Hai Shan ^b   Yang, Zhi Jie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

89SrCl2; Bone metastases; IL 2; Radionuclide therapy; TNF

Indexed keywords

CHLORIDE; INTERLEUKIN 2; STRONTIUM 89; TUMOR NECROSIS FACTOR ALPHA; STRONTIUM; STRONTIUM CHLORIDE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE; BLOOD; BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METASTASIS; MIDDLE AGED; PAIN; STATISTICS; TREATMENT OUTCOME;

BONE NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAIN; STATISTICS; STRONTIUM; STRONTIUM RADIOISOTOPES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249064677     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
2. Campa JA III, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med. 1992;22:3-10.
3. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. U Cal Public Pharmacol. 1942;2:117-149.
4. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997;24:1210-1214.
5. Kraeber-Bodéré F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000;27:1487-1493.
6. Kasalický J, Krajská V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25:1362-1367.
7. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001;28:788-798.
8. Pardoll D. T cells take aim at cancer. Proc Natl Acad Sci U S A. 2002;99:15840-15842.
9. 2 [in Chinese]. Chin J Nucl Med. 2004;24:220-221.
10. Black GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12:447-454.
11. Lin XT. Assessment of radionuclide therapy on the patients with painful bone metastases [in Chinese]. Chin J Nucl Med. 1995;15:123.
12. Wittes R. Manual of Oncologic Therapeutics. Philadelphia, PA: Lippincott; 1989:1-318.
13. Gong FL. Medical Immunology. 1st ed. Beijing, China: Science Publication; 2003:238-252.
14. Orditura M, Romano C, De Vita F, et al. Behaviour of interleukin-2 serum levels in advanced non-small cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother. 2000;49:530-536.
15. Fischer JR, Schindel M, Bulzebruck H, et al. Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis. J Cancer Res Clin Oncol. 2000;126:730-733.
16. Logan TF, Gooding WE, Whiteside TL, et al. Biological response modulation by tumor necrosis factor alpha (TNF-alpha) in a phase Ib trial in cancer patients. J Immunother. 1997;20:387-398.
17. Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer. 1996;74:1908-1915.
18. Wong GH, Kaspar RL, Zweiger G, et al. Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. J Cell Biochem. 1996;60:56-60.
19. De Vita F, Orditura M, Infusino S, et al. Increased serum levels of tumor necrosis factor-alpha are correlated to soluble intercellular adhesion molecule-1 concentrations in non-small cell lung cancer patients. Int J Mol Med. 1998;1:605-608.
20. Wu S, Boyer CM, Whitaker RS, et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993;53:1939-1944.
21. Hafner M, Orosz P, Kruger A, et al. TNF promotes metastases by impairing natural killer cell activity. Int J Cancer. 1996;66:388-392.
22. Silberstein EB. Advances in our understanding of the treatment of painful bone metastases. J Nucl Med. 2000;41:655-657.
23. 153Sm-EDTMP with radionuclide imaging [in Chinese]. Chin J Biologicals. 2002;15:374-375.